Premium
Successful Anti‐TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental Glomerulosclerosis
Author(s) -
Leroy S.,
Guigonis V.,
Bruckner D.,
EmalAglae V.,
Deschênes G.,
Bensman A.,
Ulinski T.
Publication year - 2009
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2009.02550.x
Subject(s) - medicine , immunosuppression , discontinuation , focal segmental glomerulosclerosis , infliximab , proteinuria , disease , tumor necrosis factor alpha , kidney disease , urology , surgery , gastroenterology , kidney
Posttransplant recurrence of focal and segmental glomulosclerosis (FSGS) occurs in ∼30% of patients, and remains after uncontrolled despite increased immunosuppression and plasma exchanges (PE) in ∼30% of cases. New immunosuppressive drugs might then be warranted. We report the case of a 15‐year‐old boy with FSGS leading to end‐stage renal disease (ESRD) who presented with an early posttransplant recurrence of disease. Reinforced immunosuppression and PE resulted in partial and transient disease control, but proteinuria significantly decreased with anti‐TNFα treatment (infliximab then etanercep). This is the first case report of successful anti‐TNFα treatment despite a constant high activity of FSGS, as demonstrated by relapse after discontinuation of anti‐TNFα agents.